Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
Mariangela Russo(Candiolo Cancer Institute), Alberto Bardelli(IFOM)
Cited by 20
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770